Inflammasome Lab research on inflammatory disease treatment attracts $22m global investment

Research from the Inflammasome Lab performed by Dr Rebecca Coll (pictured) and Dr Kate Schroder, in collaboration with Dr Avril Robertson and Professor Matt Cooper (Institute for Molecular Bioscience, The University of Queensland), and Professor Luke O’Neill's team (Trinity College Dublin, UK), has attracted investment for a new start-up company to develop treatments for inflammatory disorders including Parkinson’s disease and asthma.

The €15 million (A$22 million) investment, co-led by two top global life science investment firms, Novartis Venture Fund and Fountain Healthcare Partners, is one of the largest biotech Series A investments for intellectual property originating from an Australian university.

Read the complete UQ News article

Posted by admin

ABOUT Inflammasome Lab

Inflammasome Lab is a group of researchers led by Prof Kate Schroder at the Institute for Molecular Bioscience, The University of Queensland.
We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.